Israel’s BiolineRX is to perform a Phase II clinical test combining BiolineRX’s BL-8040 with Merck’s KEYTRUDA anti-PD-1 therapy in the treatment of patients with metastatic pancreatic adenocarcinoma.

http://www.globes.co.il/en/article-biolinerx-merck-to-collaborate-on-pancreatic-cancer-treatment-1001094833